

L Number	Hits	Search Text	DB	Time stamp
1	446	benzamidine and anticoagulant	USPAT; US-PGPUB	2003/07/26 16:56

EAST
10/073, 985

10/ 073,985

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3	Feb 24 PCTGEN now available on STN
NEWS	4	Feb 24 TEMA now available on STN
NEWS	5	Feb 26 NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26 PCTFULL now contains images
NEWS	7	Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24 PATDPAFULL now available on STN
NEWS	9	Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11 Display formats in DGENE enhanced
NEWS	11	Apr 14 MEDLINE Reload
NEWS	12	Apr 17 Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21 New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28 RDISCLOSURE now available on STN
NEWS	16	May 05 Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19 Simultaneous left and right truncation added to WSCA
NEWS	20	May 19 RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06 Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06 PASCAL enhanced with additional data
NEWS	23	Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25 HSDB has been reloaded
NEWS	25	Jul 16 Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21 Identification of STN records implemented
NEWS	27	Jul 21 Polymer class term count added to REGISTRY
NEWS	28	Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS EXPRESS		April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

10/ 073,985

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:52:44 ON 26 JUL 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:52:56 ON 26 JUL 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2003 HIGHEST RN 555152-78-8

DICTIONARY FILE UPDATES: 25 JUL 2003 HIGHEST RN 555152-78-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10073985.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

10/ 073,985

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 16:53:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 172 TO ITERATE

100.0% PROCESSED 172 ITERATIONS 99 ANSWERS
SEARCH TIME: 00.00.01

L2 99 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 148.15 148.36

FILE 'CAPLUS' ENTERED AT 16:53:30 ON 26 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jul 2003 VOL 139 ISS 5
FILE LAST UPDATED: 25 Jul 2003 (20030725/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 2 L2



=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:795787 CAPLUS
DOCUMENT NUMBER: 132:35700
TITLE: Preparation of benzamidine derivatives as activated blood coagulation factor X inhibitors
INVENTOR(S): Nakagawa, Tadakiyo; Sagi, Kazuyuki; Yoshida, Kaoru; Fukuda, Yumiko; Shoji, Masataka; Takehana, Shunji; Kayahara, Takashi; Takahara, Akira
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 9964392 A1 19991216 WO 1999-JP3055 19990608
 W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
 DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
 JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2334476 AA 19991216 CA 1999-2334476 19990608
 AU 9940604 A1 19991230 AU 1999-40604 19990608
 AU 758567 B2 20030327
 EP 1086946 A1 20010328 EP 1999-923959 19990608
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI
 US 2001056123 A1 20011227 US 2000-731729 20001208
 US 6410538 B2 20020625
 US 2002107290 A1 20020808 US 2002-73985 20020214
 PRIORITY APPLN. INFO.: JP 1998-159627 A 19980608
 JP 1998-159628 A 19980608
 WO 1999-JP3055 W 19990608
 US 2000-731729 A1 20001208

OTHER SOURCE(S): MARPAT 132:35700
 GI



AB The title compds. I [L is CH₂CH₂, etc.; Z₁ is CH:CHCOR₂, etc.; R₂ is OH, etc.; Y is CH:CH, etc.; V₁ is, for example, H, (un)substituted benzoyl, etc.; extensive details on V₁ are given] are prepd. I are useful as antithrombotics. In an in vitro test for inhibiting activity against activated blood coagulation factor X, the title compd. II.2CF3CO₂H showed pIC₅₀ of 8.1.

IT 252262-15-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of benzamidine derivs. as activated blood coagulation factor X inhibitors)

RN 252262-15-0 CAPLUS

10/ 073,985


CN Benzenepropanoic acid, 4-(aminoiminomethyl)-2-[[(2R)-1-(2-naphthalenylsulfonyl)-2-pyrrolidinyl]methoxy]-, mono(trifluoroacetate)
(9CI) (CA INDEX NAME)

CM 1

CRN 252262-14-9

CMF C25 H27 N3 O5 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:509180 CAPLUS

DOCUMENT NUMBER: 129:161414

TITLE: Preparation of benzamidine derivatives as anticoagulants

INVENTOR(S): Takayanagi, Masaru; Sagi, Kazuyuki; Nakagawa, Tadakiyo; Yamanashi, Masahiro; Kayahara, Takashi; Takehana, Shunji; et al.

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 453 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 9831661 A1 19980723 WO 1998-JP176 19980119
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,
 KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
 NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
 UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 AU 9854975 A1 19980807 AU 1998-54975 19980119
 AU 731819 B2 20010405
 EP 976722 A1 20000202 EP 1998-900422 19980119
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI
 PRIORITY APPLN. INFO.: JP 1997-6783 A 19970117
 JP 1997-194602 A 19970718
 JP 1997-331887 A 19971202
 WO 1998-JP176 W 19980119
 OTHER SOURCE(S): MARPAT 129:161414
 GI



AB The title compds. I [L = CH₂CH₂, NWCOCH₂, etc.; W = H, alkyl, etc.; Y = CH:CH, CONH, etc.; Z = H, alkyl, halo, etc.; when L is CH₂CH₂, V is benzoyl, cinnamoyl, etc., having substituents; further details on V are given] are prepd. These compds. show anticoagulant effects based on their excellent effects of inhibiting activated blood coagulation factor X, which makes them useful as anticoagulants. In in vitro tests for the inhibition of activated blood coagulation factor X, compds. of this invention showed pIC₅₀ values of 5.5 to 8.1.

IT 210958-43-3P 210958-45-5P 210958-47-7P
 210958-49-9P 210958-51-3P 210958-53-5P
 210959-15-2P 210959-21-0P 210959-23-2P
 210959-25-4P 210959-27-6P 210959-61-8P
 210960-13-7P 210960-15-9P 210960-17-1P
 210960-19-3P 210960-21-7P 210960-23-9P
 210960-25-1P 210960-27-3P 210960-29-5P
 210960-31-9P 210960-33-1P 210960-35-3P
 210960-37-5P 210960-39-7P 210960-41-1P
 210960-43-3P 210960-45-5P 210960-47-7P
 210960-49-9P 210960-51-3P 210960-53-5P
 210960-55-7P 210960-57-9P 210960-59-1P
 210960-61-5P 210960-63-7P 210960-65-9P
 210960-67-1P 210960-69-3P 210960-71-7P
 210960-73-9P 210960-85-3P 210960-87-5P
 210960-89-7P 210961-21-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/ 073,985

(prepn. of benzamidine derivs. as anticoagulants)

RN 210958-43-3 CAPLUS


CN Phosphonic acid, [4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidinyloxy)phenyl]ethyl]amino]sulfonyl]phenyl]-, monoethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210958-42-2

CMF C29 H37 N4 O7 P S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210958-45-5 CAPLUS

CN Phosphonic acid, [4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidinyloxy)phenyl]ethyl]amino]sulfonyl]phenyl]-, diethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210958-44-4

CMF C31 H41 N4 O7 P S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210958-47-7 CAPLUS

CN Phosphonic acid, [4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]phenyl]-, diethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210958-46-6

CMF C33 H44 N5 O7 P S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210958-49-9 CAPLUS

CN Phosphonic acid, [4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]phenyl]-, monoethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210958-48-8

CMF C31 H40 N5 O7 P S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210958-51-3 CAPLUS

CN Phosphonic acid, [4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]phenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210958-50-2

CMF C29 H36 N5 O7 P S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210958-53-5 CAPLUS


CN Benzoic acid, 4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-(aminoiminomethyl)phenyl]methyl]ethyl]amino]sulfonyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210958-52-4

CMF C24 H25 N5 O5 S

Absolute stereochemistry.




10/ 073,985

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 210959-15-2 CAPLUS

CN Benzenecarboximidamide, 3-[2-[[[(7,7-dimethylbicyclo[2.2.1]hept-1-yl)methyl]sulfonyl]amino]ethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210959-14-1


CMF C19 H29 N3 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/ 073,985

RN 210959-21-0 CAPLUS
CN Benzenecarboximidamide, 3-[2-[(2-naphthalenylsulfonyl)amino]ethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210959-20-9
CMF C19 H19 N3 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 210959-23-2 CAPLUS
CN Benzenecarboximidamide, 3-[2-[[[4-(aminoiminomethyl)phenyl]sulfonyl]amino]ethoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210959-22-1
CMF C16 H19 N5 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 210959-25-4 CAPLUS
CN Benzamide, 4-[[[2-[3-(aminoiminomethyl)phenoxy]ethyl]amino]sulfonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210959-24-3
CMF C16 H18 N4 O4 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 210959-27-6 CAPLUS
CN Benzenecarboximidamide, 3-[2-[[[4-bromophenyl)sulfonyl]amino]ethoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 210959-26-5
CMF C15 H16 Br N3 O3 S



CM 2

10/ 073,985


CRN 76-05-1
CMF C2 H F3 O2



RN 210959-61-8 CAPLUS
CN Benzenecarboximidamide, 3-[3-[(2-naphthalenylsulfonyl)amino]propoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210959-60-7
CMF C20 H21 N3 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 210960-13-7 CAPLUS
CN Benzenecarboximidamide, 3-[(2S)-2-[(ethylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-12-6
CMF C23 H32 N4 O4 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-15-9 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-2-[(ethylsulfonyl)amino]-3-[4-[[1-[(ethylsulfonyl)oxy]-4-piperidinyl]oxy]phenyl]propoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-14-8

CMF C25 H36 N4 O7 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 073,985



RN 210960-17-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-[(2S)-3-[3-(aminoiminomethyl)phenoxy]-2-[(ethylsulfonyl)amino]propyl]phenoxy]-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-16-0

CMF C31 H38 N4 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-19-3 CAPLUS

CN Benzenecarboximidamide, 3-[(2S)-2-[(butylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-18-2

CMF C25 H36 N4 O4 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-21-7 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-2-[(butylsulfonyl)amino]-3-[4-[[1-[(butylsulfonyl)oxy]-4-piperidinyl]oxy]phenyl]propoxy]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-20-6

CMF C29 H44 N4 O7 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 073,985



RN 210960-23-9 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-[(2S)-3-[3-(aminoiminomethyl)phenoxy]-2-[(butylsulfonyl)amino]propyl]phenoxy]-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-22-8

CMF C33 H42 N4 O6 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-25-1 CAPLUS

CN Benzenecarboximidamide, 3-[(2S)-2-[(phenylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-24-0

CMF C27 H32 N4 O4 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-27-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-[(2S)-3-[3-(aminoiminomethyl)phenoxy]-2-[(phenylsulfonyl)amino]propyl]phenoxy]-2-[(phenylsulfonyl)amino]propyl]phenoxy-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-26-2

CMF C35 H38 N4 O6 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 073,985



RN 210960-29-5 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-2-[(2-naphthalenylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-28-4

CMF C31 H34 N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-31-9 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-3-(4-hydroxyphenyl)-2-[(2-naphthalenylsulfonyl)amino]propoxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-30-8

CMF C26 H25 N3 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-33-1 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[4-[(2S)-3-[3-(aminoiminomethyl)phenoxy]-2-[(2-naphthalenylsulfonyl)amino]propyl]phenoxy]-, phenylmethyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-32-0

CMF C39 H40 N4 O6 S

Absolute stereochemistry.




10/ 073,985

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-35-3 CAPLUS


CN Benzenecarboximidamide, 3-[(2R)-2-[(ethylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-34-2

CMF C23 H32 N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-37-5 CAPLUS

CN Benzenecarboximidamide, 3-[(2R)-2-[(phenylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-36-4

CMF C27 H32 N4 O4 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-39-7 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-3-[4-[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]-2-[(phenylsulfonyl)amino]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-38-6

CMF C29 H35 N5 O4 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 073,985



RN 210960-41-1 CAPLUS


CN 1-Piperidinecarboximidamide, 4-[4-[(2S)-3-[3-(aminoiminomethyl)phenoxy]-2-[(phenylsulfonyl)amino]propyl]phenoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-40-0

CMF C28 H34 N6 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-43-3 CAPLUS

CN Benzenecarboximidamide, 3-[(2S)-2-[(ethylsulfonyl)amino]-3-[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-42-2

CMF C25 H35 N5 O4 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-45-5 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-2-[(butylsulfonyl)amino]-3-[4-[[1-(1-iminoethyl)-4-piperidinyloxy]phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-44-4

CMF C27 H39 N5 O4 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 073,985



RN 210960-47-7 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-3-[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]-2-[(2-naphthalenylsulfonyl)amino]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-46-6

CMF C33 H37 N5 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-49-9 CAPLUS

CN Benzenecarboximidamide, 3-[(2S)-3-[4-[[[(3S)-1-(1-iminoethyl)-3-pyrrolidinyl]oxy]phenyl]-2-[(phenylsulfonyl)amino]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-48-8

CMF C28 H33 N5 O4 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-51-3 CAPLUS


CN Benzenecarboximidamide, 3-[(2S)-2-[(phenylsulfonyl)amino]-3-[4-(4-piperidinylmethyl)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-50-2

CMF C28 H34 N4 O3 S

Absolute stereochemistry.




CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/ 073,985



RN 210960-53-5 CAPLUS


CN 2-Propenoic acid, 3-[4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidinyloxy)phenyl]ethyl]amino]sulfonyl]phenyl]-, (2E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-52-4

CMF C30 H34 N4 O6 S


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-55-7 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidinyloxy)phenyl]ethyl]amino]sulfonyl]phenyl]-, ethyl ester, (2E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-54-6

CMF C32 H38 N4 O6 S

10/ 073,985


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-57-9 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidin-1-yloxy)phenyl]ethyl]amino]sulfonyl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)


CM 1

CRN 210960-56-8

CMF C28 H32 N4 O6 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-59-1 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidinyloxy)phenyl]ethyl]amino]sulfonyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-58-0

CMF C29 H34 N4 O6 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-61-5 CAPLUS

CN Benzoic acid, 4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidinyloxy)phenyl]ethyl]amino]sulfonyl]-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-60-4

CMF C30 H36 N4 O6 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-63-7 CAPLUS

CN Benzoic acid, 4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-62-6

CMF C30 H35 N5 O6 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-65-9 CAPLUS

CN Benzoic acid, 4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]-, methyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-64-8

CMF C31 H37 N5 O6 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-67-1 CAPLUS

CN Benzoic acid, 4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-66-0

CMF C32 H39 N5 O6 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-69-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[4-[[1-(1-iminoethyl)-4-piperidinyloxy]phenyl]methyl]ethyl]amino]sulfonyl]phenyl]-, (2E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-68-2

CMF C32 H37 N5 O6 S

Absolute stereochemistry.
Double bond geometry as shown.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-71-7 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]phenyl]-, ethyl ester, (2E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-70-6

CMF C34 H41 N5 O6 S

Absolute stereochemistry.
Double bond geometry as shown.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-73-9 CAPLUS

CN Benzoic acid, 2-[[[(1S)-2-[3-(aminoiminomethyl)phenoxy]-1-[[4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]methyl]ethyl]amino]sulfonyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 210960-72-8

CMF C30 H35 N5 O6 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 210960-85-3 CAPLUS


CN Benzenecarboximidamide, 4-iodo-3-[(2S)-2-[(phenylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-84-2

CMF C27 H31 I N4 O4 S


Absolute stereochemistry.



CM 2

10/ 073,985

CRN 76-05-1
CMF C2 H F3 O2




RN 210960-87-5 CAPLUS
CN Benzenepropanoic acid, 4-(aminoiminomethyl)-.alpha.-oxo-2-[(2S)-2-
[(phenylsulfonyl)amino]-3-[4-(4-piperidinyloxy)phenyl]propoxy]-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 210960-86-4
CMF C30 H34 N4 O7 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 210960-89-7 CAPLUS
CN Benzenepropanoic acid, 4-(aminoiminomethyl)-2-[(2S)-3-[4-[[1-(1-
iminoethyl)-4-piperidinyl]oxy]phenyl]-2-[(phenylsulfonyl)amino]propoxy]-
.alpha.-oxo-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 210960-88-6
CMF C32 H37 N5 O7 S

Absolute stereochemistry.


10/ 073,985



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 210961-21-0 CAPLUS

CN Acetic acid, [[[2-[3-(aminoiminomethyl)phenoxy]ethyl][4-[[1-(1-iminoethyl)-4-piperidinyloxy]phenyl]amino]sulfonyl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 210961-20-9


CMF C24 H31 N5 O6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 210958-42-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of benzamidine derivs. as anticoagulants)

RN 210958-42-2 CAPLUS

CN Phosphonic acid, [4-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-piperidinyloxy)phenyl]ethyl]amino]sulfonyl]phenyl]-, monoethyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 210963-43-2P 210963-48-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of benzamidine derivs. as anticoagulants)

RN 210963-43-2 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[(2S)-3-[3-(aminoiminomethyl)phenoxy]-2-[(phenylsulfonyl)amino]propyl]phenyl]methyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 210963-48-7 CAPLUS

CN Benzoic acid, 2-[[[(1S)-1-[[3-(aminoiminomethyl)phenoxy]methyl]-2-[4-(4-


10/ 073,985

piperidinyloxy)phenyl]ethyl]amino]sulfonyl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1


CRN 210963-47-6
CMF C28 H32 N4 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:52:44 ON 26 JUL 2003)

FILE 'REGISTRY' ENTERED AT 16:52:56 ON 26 JUL 2003

L1 STRUCTURE UPLOADED
L2 99 S L1 FUL

FILE 'CAPLUS' ENTERED AT 16:53:30 ON 26 JUL 2003

L3 2 S L2

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
9.91	158.27

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
------------	-------

10/ 073,985

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 16:54:36 ON 26 JUL 2003

L Number	Hits	Search Text	DB	Time stamp
1	446	benzamidine and anticoagulant	USPAT; US-PGPUB	2003/07/26 16:56